drugset / Trial / NCT02361424
Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)
Non-randomizedCrossoverTriple-blindTreatment
Summary
The purpose of this study is to assess the safety and efficacy on cognitive impairment and functioning of several doses of PXT00864 (new fixed combination of acamprosate and baclofen at low dose) in patients with mild Alzheimer Disease.
Timeline
- Start
- 2013-02
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acamprosate | Small molecule | 0.4 mg | Oral |
| Subject | Acamprosate | Small molecule | 1 mg | Oral |
| Subject | Acamprosate | Small molecule | 20 mg | Oral |
| Subject | Baclofen | Small molecule | 6 mg | Oral |
| Subject | Baclofen | Small molecule | 12 mg | Oral |
| Subject | Baclofen | Small molecule | 15 mg | Oral |